Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034 - Concepedia

Concepedia

Publication | Open Access

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

DOI Full Paper Access

561

Citations

22

References

2009

Year

Martin J. van den Bent, Alba A. Brandes, R. Rampling, Mathilde C.M. Kouwenhoven, Johan M. Kros, Paul M. Clément, M. Frénay, Mario Campone, Jean‐François Baurain, Jean-Paul Armand,

Journal of Clinical Oncology

Abstract

Erlotinib has insufficient single-agent activity in unselected GBM. No clear biomarker associated with improved outcome to erlotinib was identified.

References

	Year	Citations

Page 1